Johnson & Johnson cash flow to debt ratio of 51.18% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Johnson & Johnson's free cash flow has decreased -0.73% from $19.84G last year to $19.70G, signaling decreasing performance

Johnson & Johnson's debt to equity ratio is 0.22, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Johnson & Johnson's debt has decreased relative to shareholder equity from 0.51 last year to 0.22 today, signaling strengthened financials

Johnson & Johnson has a net debt to EBITDA ratio of 0.69x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Johnson & Johnson's interest coverage ratio of 31.97 indicates that earnings with good margin can cover interest payments on company debt

Johnson & Johnson's profit margin has increased (37.87%) in the last year from 15.84% to 21.83%, signaling increasing performance

Johnson & Johnson's short-term assets of $55.62G exceed its short-term liabilities of $54.13G

Johnson & Johnson's return on assets of 10.47% is higher than the 5.00% threshold, indicating efficient asset utilization

Johnson & Johnson's return on equity of 26.26%, is higher than 15.00%, indicating good performance

Johnson & Johnson's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Johnson & Johnson had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Johnson & Johnson has positive free cash flow, indicating the company generates cash after capital expenditures

Johnson & Johnson has a free cash flow yield of 3.53%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Johnson & Johnson's yearly earnings has increased 90.56% since last year from $14.07G to $26.80G, signaling increasing performance

Johnson & Johnson's yearly revenue has increased 6.05% since last year from $88.82G to $94.19G, signaling increasing performance

ROIC 13.60% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Johnson & Johnson's 3-year revenue CAGR of 5.60% is positive, indicating growing revenue over the past 3 years

Johnson & Johnson had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Johnson & Johnson had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Johnson & Johnson is overvalued relative to its fair value price of 81.99 based on Discounted Cash Flow model

Johnson & Johnson has an earnings yield of 3.72%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Johnson & Johnson is overvalued relative to its fair value price of 107.55 based on EBITDA multiple model

Johnson & Johnson has an EV/EBITDA ratio of 17.49x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Johnson & Johnson is overvalued relative to its fair value price of 138.07 based on Earnings Fair Value model

Johnson & Johnson has a price-to-book ratio of 6.97x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Johnson & Johnson has a price-to-sales ratio of 5.78x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue